Barclays Raises Price Targets on Constellium, Entegris and DexCom
Barclays lifted price targets on Constellium to $30, Entegris to $224 and DexCom to $120, per Dow Jones Newswires citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Barclays raised its price target on Constellium shares to $30 from $28. According to Dow Jones Newswires, citing Benzinga, the bank also increased its target on Entegris to $224 from $212 and on DexCom to $120 from $115.
The Overweight rating on Entegris and DexCom was maintained. The source material gives no further detail on these decisions.
why it matters
A single broker's target change usually affects individual stocks rather than the broader market. For investors, such notes show how analysts view these companies, but they are not a forecast of where prices will go.
tags
instruments
sources
- Constellium Price Target Raised to $30.00/Share From $28.00 by Barclays — Dow Jones Newswires, 30 October 2026 at 14:23 UTC
- Entegris Price Target Raised to $224.00/Share From $212.00 by Barclays — Dow Jones Newswires, 30 October 2026 at 14:32 UTC
- DexCom Price Target Raised to $120.00/Share From $115.00 by Barclays — Dow Jones Newswires, 30 October 2026 at 14:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗